Related Experiment Video

Updated: May 2, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

750

Reducing methylglyoxal as a therapeutic target for diabetic heart disease

Branka Vulesevic1, Ross W Milne2, Erik J Suuronen1

  • 1*Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Canada, K1Y 4W7.

Biochemical Society Transactions
|March 21, 2014
PubMed

Insights

Diabetes damages heart tissue via high blood glucose, harming endothelial cells. Methylglyoxal, a toxic byproduct, contributes to this damage, highlighting its potential as a therapeutic target for diabetic cardiovascular complications.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disorders
  • Cellular Biology

Background:

  • Diabetes mellitus is a significant risk factor for cardiovascular diseases.
  • High blood glucose levels in diabetes lead to endothelial cell damage, impairing heart function.
  • Methylglyoxal (MGO), a toxic byproduct of glycolysis, exacerbates endothelial dysfunction.

Purpose of the Study:

  • To investigate the role of methylglyoxal in diabetes-induced cardiovascular complications.
  • To explore the failure of the glyoxalase system in detoxifying methylglyoxal during diabetes.
  • To identify methylglyoxal as a potential therapeutic target for managing diabetic cardiovascular disease.

Main Methods:

  • Review of existing literature on diabetes, cardiovascular disease, and methylglyoxal metabolism.
  • Analysis of the mechanisms by which methylglyoxal damages cardiac endothelial cells.
  • Examination of the glyoxalase system's role and limitations in diabetic conditions.

Main Results:

  • Methylglyoxal directly contributes to endothelial cell damage in diabetes.
  • The glyoxalase system, a natural defense against methylglyoxal, is overwhelmed and fails in diabetic states.
  • Advanced glycation end-products (AGEs) are formed from methylglyoxal, further contributing to pathology.

Conclusions:

  • Methylglyoxal is a key mediator of cardiovascular complications in diabetes.
  • Targeting methylglyoxal and enhancing the glyoxalase system show promise for therapeutic interventions.
  • Further understanding of these pathways can lead to novel strategies for treating diabetic heart disease.

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K